Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 24, 2025eJHaemOpen Access

Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

HMHira MianJHJennifer S. HarperHLHoa H. Le

Discussion

Loading...

Member takes

Overview

Real-world data reveals poor clinical outcomes in triple-class-exposed patients with multiple myeloma, highlighting urgent need for innovative therapies.

Key Points

  • Median time to next treatment or death was 6.8 months, indicating limited efficacy of existing therapies.
  • From 656 patients, most prevalent prior therapies included daratumumab (98.5%) and pomalidomide (86.0%), revealing treatment preferences.
  • A total of 137 subsequent treatment regimens were documented, with teclistamab being the most common, demonstrating therapeutic diversity.
  • This first real-world analysis indicates urgent needs for novel treatments due to frequent retreatment and poor outcomes.

Cite This Study

Mian et al. (2025) studied this question.

synapsesocial.com/papers/68d6e0fc8b2b6861e4c3f506https://doi.org/10.1002/jha2.70145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma2024 · 20 citations
  3. 3Class comparison of BCMA-directed therapies in relapsed multiple myeloma.2024 · 1 citations
  4. 4Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.2024
  5. 5Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025